Medical ANAPIX, imagery real time of the skin

December 2017

SKINAPP : the imagery real time of the skin for the dermatologists and health professionals

SKINSHOT : the useful selfie for the individuals

Medical ANAPIX is specialized in the optical imagery of the skin,

- light and communicating because she calls on the capacities of the smartphones to acquire the images and to diffuse them,

- interactive because these images are available, easy to handle and transferable in real time on Internet via web-applications,

- innovating, because several algorithms from the machine learning can be solicited to analyze them, to detect the melanomas in particular.

Medical ANAPIX thus proposes:

- a service for the dermatologists and general doctors which deals with all their requirements in optical imagery for the lesions for the skin. An application on smartphone makes it possible to make photography of it easily, while their analysis can be carried out immediately or remote on a local or distant computer. The small lesions, in particular mélanocytaires (beauty spots) profit from a treatment specific for a help to the diagnosis and the therapeutic decision if they are acquired using an objective dermoscopic (flunks with annular lighting) set at the objective of the smartphone.

- an application functioning on smartphone, for the general public, allowing each one to make the inventory of fixtures of its beauty spots (and those of its family) and to locate the lesions at the risk likely to become melanomas which thus should be supervised.

Interview of Bernard FERTIL, President ofmedical ANAPIX
  • Editorial Committee: Where would you situate your company's innovation?

Bernard FERTIL (BF) : Cancers represent the first cause of mortality in France (30% of the deaths). In 2012, in the European Union of the 27.82 100 new cases of melanoma were listed. Mortality by melanoma is estimated at 15,700 deaths. In the USA, in 2013, the last estimates give 76,690 new cases of invading melanoma and 9,480 deaths charged to the melanoma (either 1 death every hour). It is the 5th most common cancer among the men and women. Detected at an early stage, the melanoma is cured in the majority of the cases by simple a excérèse (the lesion is removed surgically). Discovered at a late stage, the survival of the patient is concerned because in particular of the propensity of the melanoma to induce metastases via the lymphatic system. Thus, it is advisable to detect an abnormally evolving beauty spot as soon as possible.

However, it is very paradoxical to note that the dermatologists, whose significant portion of the medical expertise is founded on the visual examination of the lesions however call very little on the digital imagery, contrary to radiologists and other experts already strongly equipped (ophtalmologists, echographists, dental surgeons…). At most they use magnifying glasses to observe structures in detail (dermoscope), specific lightings to reveal specific cutaneous infections (lamp of Wood). However, the whole of the profession agrees to say that the digital imagery could do many favours to them (followed by the evolution of the lesions, diagnosis computer-assisted, tele diagnosis, filing, teaching…). Actually, the only specific systems which would enable them to acquire images, to visualize them instantaneously and to file them strongly interfere with their daily practice, have a closed structure and a prohibitory cost (>15 K€).

In addition, the general public is sensitized more and more with the tracking of the melanoma. However, because of strong decrease amongst dermatologists and of the ignorance of the general practitioners on this question, it is difficult to obtain, in a reasonable time, a consultation which either would reassure the patient, or would allow an early tracking largely supporting its chances of survival.

  • EC: How did you go about developing your project?

BF : The proposed offer today by the company is the 8 year old fruit of R & D at the laboratory of and the system information sciences (LSIS, UMR CNRS 6168 of the Aix-Marseilles University) in collaboration with Professeur Jean-Jacques GROB, Chief of the Service of Dermatologist-vénérologie in CHU de Marseille. The algorithms designed within the framework of this academic research required the availability of images of lesions to build them (this operation is carried out by training supervised starting from images). We had thus developed a chain of acquisition of these images allowing to recover them with the source, with the cabinet of the dermatologists. To use these algorithms thereafter, It was also necessary to be able to have images of lesions obtained in a medical context. The creation of a startup seemed the best means to implement them in the true life, those of the health professionals and the patients. The South-eastern SATT dealt with part of the maturation of the interface of use, a secure waiter health was requested to manage the whole of the data-processing transactions related to the management of the patient files associated with the images.

  • EC: What actions and deployments are currently in the pipeline?

BF : The management and the analysis of the images are done by means of the web-application SKINAPP which integrates features different according to type of user: A first version of the module DIAMELA, tool of assistance to the diagnosis of the melanomas intended for the dermatologists, will be marketed at the beginning of 2018. The clinical evaluation of this medical device proceeded of March 2010 at the end of 2012. It presents performances at least equal to those of an expert dermatologist. The module SKINAN, whose clinical trials are in hand, is addressed, as for him, with the health professionals not dermatologists (general doctors included). It is a tool of decision-making aid therapeutic concerning the small lesions of the skin. It automatically sorts the images acquired by these not - specialists not to address to the dermatologists who “suspect” images for an TV-expert testimony, and thus to limit the intervention of the specialists to the relevant cases.

The application Smartphone SKINSHOT for the general public is founded on a classifior of lesions mélanocytaires specifically designed to locate the original lesions. It exploits for that the sign of diagnosis of the Ugly Duckling (world exclusiveness).

All medical products ANAPIX fall under an optics of evolution towards TV-expert testimony in dermatology, that it automatic or is assisted by dermatologists recruited for this purpose. Several research projects are in hand, concerning inter alia the evaluation with clinical trials of our module of early detection of the melanoma, the optimization of the assistance to the diagnosis brought to the dermatologists of module DIAMELA by iconographic impregnation, the management of the exchanges between general doctors and dermatologists, within the framework of the course of care and the opinion request of expert testimony.

  • EC: Why did you join the SCS Cluster?

BF: According to its own terms, the SCS Cluster is presented in the form of “an inevitable actor and recognized in the field as of secure communicating solutions”! It seems to me that this definition includes our activity well and justifies our adhesion fully.

 

  • EC: Has the SCS Cluster brought you what you were looking for?

BF : Once member of the SCS Cluster, which marks more is its dynamism and its relevance. We are regularly solicited by them for various well targeted actions and their assistance is very notable. Thus, for example, we currently profit from their support to present a request for subsidy to the area.

  • EC: What do you expect of the Cluster in the future?

BF: A startup as ours initially needs a maximum of exposure for its products and solutions. We currently launch an early campaign of tracking of the melanoma near the great groups and great organizations concerned with the health of their staffs. We also wish to diffuse our application SKINSHOT bound for the general public. There is no doubt that the audience of the SCS Cluster is an excellent ground with this intention.

Contact:

FERTIL Bernard

Postal address: 100 impasse des Houillères, 13590 Meyreuil

Phone: 06 63 77 02 01

Email: bernard.fertil@anapix-medical.com

Website: www.anapix-medical.com

Twitter: @anapixmedical

LinkedIn: Medical ANAPIX

Facebook: anapixmedical

 
December 2017